U.S. Banks Stock News

Some investors may be wondering if WEC Energy Group stock at around US$111.67 is offering fair value right now, or if the price is getting ahead of itself. Over the very short term the stock is relatively flat, declining 0.4% over the last week and 3.5% over the last month, while the year to date return sits at 4.9% and the 1 year return at 8.9%, with 3 and 5 year returns of 44.3% and 40.9% respectively. Recent coverage of WEC Energy Group has focused on its position in the regulated...

Humana Inc. recently began full operations at its new US$83 million, 162,000-square-foot CenterWell Pharmacy mail-order distribution center in Orlando, which can process up to 64,000 prescriptions per day and initially employs more than 165 people. Beyond serving Humana members, the Orlando facility expands CenterWell’s payer-agnostic mail-order capabilities, supporting emerging direct-to-consumer and direct-to-employer medication access partnerships nationwide. Next, we’ll examine how this...

Elastic (ESTC) is back in focus after reporting fourth quarter and full year results, with revenue of US$450.68 million and quarterly net income of US$435.9 million, alongside fresh double digit growth guidance for fiscal 2027. See our latest analysis for Elastic. The earnings beat and double digit fiscal 2027 guidance have coincided with a sharp rebound in momentum, with the stock posting a 21.41% 1 month share price return but a 1 year total shareholder return that is still down 37.40%. If...

Genpact (NYSE:G) has been placed in the highest tier by HFS Research for its work in orchestrating and transforming Global Capability Centers. The recognition centers on Genpact's use of AI and platform-led services to support these centers. The ranking underscores the company's role in helping enterprises manage complex operational requirements through Global Capability Centers. For you as an investor, this recognition sits at the intersection of business process management, AI and global...

Adobe recently highlighted that AI-assisted shopping referrals in the UK are now converting into sales more effectively than traditional online search, while its own Firefly generative AI is displacing legacy stock-photo revenue faster than expected but still driving very strong AI-related subscription growth. At the same time, Adobe Analytics has been recognized as a leading digital analytics platform and prominent investors are publicly emphasizing Adobe’s entrenched role in creative...

Lululemon athletica (LULU) has capped months of governance tension with founder Dennis “Chip” Wilson by signing a cooperation agreement that reshapes its board and introduces fresh oversight for shareholders. See our latest analysis for lululemon athletica. The governance truce comes after a tough stretch for investors, with the share price down 37.7% year to date and the 1 year total shareholder return falling 58.6%. A 3.6% 7 day share price gain hints at improving sentiment as earnings and...

In recent days, AppLovin drew heightened attention after strong first-quarter results and broad analyst optimism coincided with anticipation for the June 2026 launch of its Axon AI-powered self-serve advertising platform. A distinctive angle in this story is Meta Platforms’ decision to avoid bidding on key non-IDFA iOS ad inventory, spotlighting AppLovin’s AXON engine as a relative advantage in a technically complex segment of mobile advertising. We'll now explore how the Axon AI platform...

Shareholders of Bath & Body Works, Inc. ( NYSE:BBWI ) will be pleased this week, given that the stock price is up 18...

It looks like Agnico Eagle Mines Limited ( NYSE:AEM ) is about to go ex-dividend in the next two days. The ex-dividend...

Tyson Foods, Inc. ( NYSE:TSN ) is about to trade ex-dividend in the next two days. The ex-dividend date is one business...

BorgWarner Inc. ( NYSE:BWA ) is about to trade ex-dividend in the next two days. The ex-dividend date is one business...

Q1 2026 earnings snapshot sets the stage for Autohome (NYSE:ATHM) Autohome (NYSE:ATHM) opened 2026 with Q1 revenue of C¥1,048.4 million and basic EPS of C¥0.38, alongside net income of C¥44.3 million, putting fresh numbers behind a stock currently trading at $17.30. Over the last few quarters, revenue has moved from C¥1,783.4 million in Q4 2024 to C¥1,453.8 million in Q1 2025 and then to C¥1,048.4 million in Q1 2026, while quarterly basic EPS has shifted from C¥2.51 to C¥2.86 and then to...

Bruker (BRKR) has drawn fresh attention after commissioning its BioSpec 18 Tesla preclinical MRI system at the Champalimaud Foundation in Lisbon. The high-field platform is aimed at advanced cancer and neuroscience research. See our latest analysis for Bruker. Bruker’s news about the BioSpec 18 Tesla system comes during a sharp upswing in the stock, with a 50.00% 30-day share price return and 46.76% 1-year total shareholder return, even though the 3- and 5-year total shareholder returns...

Wondering if Sociedad Química y Minera de Chile at around US$84.05 is still offering value after a strong run, or if you are arriving late to the story. The stock has returned 6.0% over the past week, is down 6.0% over the past month, but is up 20.5% year to date and 169.1% over the last year, which can change how the market is thinking about its risk and reward profile. Recent coverage has focused on Sociedad Química y Minera de Chile as a key player in materials and lithium related themes,...

Recent price performance and business profile Kemper (KMPR) has been under pressure recently, with the stock down 3% over the past day and 14% over the past week. This has drawn attention to how its insurance business is currently positioned. The company offers specialty auto and life insurance products across the United States through two main segments: Specialty Property & Casualty Insurance and Life Insurance. Total revenue was reported at US$4.7b. See our latest analysis for...

ATI (ATI) heads into its May 28 Bernstein Strategic Decisions Conference appearance with investors already focused on its aerospace and defense tilt, consistent earnings outperformance, and segment reshaping around higher margin materials and components. See our latest analysis for ATI. The stock’s recent run to US$170.53, with a 7 day share price return of 6.3% and a year to date share price return of 43.1%, sits alongside a very large 5 year total shareholder return. This points to momentum...

Agilent Technologies (A) has just reported Q2 2026 results with revenue of US$1,835 million and basic EPS of US$1.20, alongside trailing twelve month revenue of US$7.2 billion and EPS of US$5.00 that sit against a one year earnings growth figure of 21.3%. Over recent quarters, revenue has ranged between US$1,668 million and US$1,861 million while quarterly EPS has moved between roughly US$0.75 and US$1.53, with net profit margin across the last year at 19.6% compared to 17.6% a year earlier...

AI momentum and federal cloud access put Cellebrite DI (NasdaqGS:CLBT) in focus Fresh headlines around broader adoption of Cellebrite DI (NasdaqGS:CLBT) AI and cloud-based investigation tools, plus FedRAMP authorization for its cloud platform, have put the stock back onto investor watchlists. Project Genesis, the company’s new AI tool aimed at cutting investigation times, is seeing early customer interest, and recent updates highlight growth in annual recurring revenue along with a thicker...

If you are trying to figure out whether GE Vernova is attractively priced or already fully valued, the recent share performance gives you a lot to think about. The stock recently closed at US$996.00, with returns of 46.6% year to date and 111.9% over the last year, even though it is down 4.6% over the past week and 8.5% over the past month. Recent coverage has focused on GE Vernova as a standalone listed business following its separation from General Electric. Investors are watching how the...

AbbVie (ABBV) just received U.S. FDA approval for Decnupaz, the first antibody drug conjugate cleared to treat blastic plasmacytoid dendritic cell neoplasm, an ultra rare, aggressive blood cancer with limited options. See our latest analysis for AbbVie. AbbVie’s shares trade at US$218.63 after a 10.59% 1 month share price return, even though the stock is still down 4.66% year to date. The 1 year total shareholder return of 21.62% points to stronger underlying momentum building over time. If...

Earlier in May, Gilat Satellite Networks announced a milestone with Boeing to offer Gilat’s Sidewinder electronically steered antenna as a future line‑fit inflight connectivity option, while Boeing also secured FAA clearance to lift 737 Max output to 47 jets per month and confirmed an agreement for 200 aircraft with China. Together, these developments highlight Boeing’s efforts to restore operational momentum in commercial jets while deepening technology partnerships that could enhance...

PACCAR stock snapshot after recent performance PACCAR (PCAR) is drawing investor attention after a period where the stock is up about 22% over the past year but down around 6% over the past month and 11% over the past 3 months. At a recent close of US$112.22 and a market value near US$59.1b, PACCAR’s mix of truck manufacturing, parts distribution, and financial services provides several angles for evaluating its current pricing and recent volatility. See our latest analysis for PACCAR. For...

Over the past two weeks, Klarna Group (NYSE:KLAR) has announced multiple new partnerships across parking, retail, automotive services, vision care, and AI-driven shopping search. Arrive (EasyPark) will use Klarna to support parking payments in 15 European markets, while Lands' End expands Klarna's presence in U.S. retail. Partnerships with Tekion and EZContacts extend Klarna into automotive service department payments and the vision care market. An integration of Klarna's shopping search app...

Intellia Therapeutics recently reported positive phase III results for its CRISPR therapy lonvoguran ziclumeran in hereditary angioedema and began a rolling BLA submission to the FDA, while the FDA also lifted clinical holds on its other phase III candidate, nexiguran ziclumeran, allowing those trials to resume. These twin milestones not only move Intellia’s in vivo CRISPR programs closer to potential commercialization but also reduce clinical and regulatory uncertainty around its most...